134 related articles for article (PubMed ID: 15987079)
1. [Designer drugs and their rational use in clinical hematology].
Bukh A; D'Amore FA; Gimsing P; Hasselbalch HC; Johnsen HE; Kerndrup GB; Kristensen JS; Peterslund NA; ;
Ugeskr Laeger; 2005 May; 167(20):2180-3. PubMed ID: 15987079
[No Abstract] [Full Text] [Related]
2. [Autocrine and paracrine growth: growth factors and/or receptors as oncogenes].
Mawas C
Pathol Biol (Paris); 1992 Nov; 39(9):858-9. PubMed ID: 1538908
[No Abstract] [Full Text] [Related]
3. Hematopoietic growth factors for hematopoietic stem cell mobilization and expansion.
Möhle R; Kanz L
Semin Hematol; 2007 Jul; 44(3):193-202. PubMed ID: 17631183
[TBL] [Abstract][Full Text] [Related]
4. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project.
Bennett CL; Evens AM; Andritsos LA; Balasubramanian L; Mai M; Fisher MJ; Kuzel TM; Angelotta C; McKoy JM; Vose JM; Bierman PJ; Kuter DJ; Trifilio SM; Devine SM; Tallman MS
Br J Haematol; 2006 Dec; 135(5):642-50. PubMed ID: 17054431
[TBL] [Abstract][Full Text] [Related]
5. Colony-stimulating factor-3 receptor, watch out for polymorphisms.
Bilbao-Sieyro C; Santana G; Torres-Miñana L; Rodriguez-Medina C; Saez MN; Perera M; Lemes A; de la Iglesia S; Molero T; Gomez-Casares MT
Leukemia; 2015 Jun; 29(6):1445-6. PubMed ID: 25708716
[No Abstract] [Full Text] [Related]
6. Drug-related thrombosis in hematologic malignancies.
Nadir Y; Hoffman R; Brenner B
Rev Clin Exp Hematol; 2004 Jun; 8(1):E4. PubMed ID: 16029970
[TBL] [Abstract][Full Text] [Related]
7. Rational use of myeloid growth factors in hemato-oncology.
Boogaerts MA
Acta Clin Belg; 1999 Oct; 54(5):312-5. PubMed ID: 10555392
[No Abstract] [Full Text] [Related]
8. Hematopoietic growth factors in the treatment of acquired bone marrow failure states.
Marsh JC; Ganser A; Stadler M
Semin Hematol; 2007 Jul; 44(3):138-47. PubMed ID: 17631178
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
10. Successful Imatinib therapy as a bridge to transplant in an atypical myeloproliferative neoplasm.
Hueso T; Johnson-Ansah H; Decamp M; Maitre E; Henry A; Mensi S; Vilque JP; Chantepie S; Damaj G
Curr Res Transl Med; 2019 Nov; 67(4):149-151. PubMed ID: 31153956
[No Abstract] [Full Text] [Related]
11. Preclinical and clinical safety of monoclonal antibodies.
Tabrizi MA; Roskos LK
Drug Discov Today; 2007 Jul; 12(13-14):540-7. PubMed ID: 17631248
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic immunomodulation of hematopoietic malignancies.
Gattei V; Fonsatti E; Sigalotti L; Degan M; Di Giacomo AM; Altomonte M; Calabrò L; Maio M
Semin Oncol; 2005 Oct; 32(5):503-10. PubMed ID: 16210091
[TBL] [Abstract][Full Text] [Related]
13. The role of natalizumab in hematopoietic stem cell mobilization.
Neumann F; Zohren F; Haas R
Expert Opin Biol Ther; 2009 Aug; 9(8):1099-106. PubMed ID: 19566481
[TBL] [Abstract][Full Text] [Related]
14. [Progress in the field of hematology in the last 100 years: From chemotherapy to target-based therapy for hematologic malignancies].
Ueda R
Nihon Naika Gakkai Zasshi; 2002 Jul; 91(7):2007-11. PubMed ID: 12187666
[No Abstract] [Full Text] [Related]
15. Antibodies and hematologic malignancies.
Smith MR
Cancer J; 2008; 14(3):184-90. PubMed ID: 18536558
[TBL] [Abstract][Full Text] [Related]
16. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies.
Khubchandani S; Czuczman MS; Hernandez-Ilizaliturri FJ
Curr Opin Investig Drugs; 2009 Jun; 10(6):579-87. PubMed ID: 19513947
[TBL] [Abstract][Full Text] [Related]
17. Keeping up with neonatal infection: designer bugs, Part II.
Lott JW; Kenner C
MCN Am J Matern Child Nurs; 1994; 19(5):264-71. PubMed ID: 7990671
[No Abstract] [Full Text] [Related]
18. [New agents for solid tumours].
Raida M
Dtsch Med Wochenschr; 2006 Oct; 131(43):2407-10. PubMed ID: 17054057
[No Abstract] [Full Text] [Related]
19. Designer drugs: new directed therapies for cancer.
Feig SA
Int J Hematol; 2002 Aug; 76 Suppl 2():281-3. PubMed ID: 12430937
[TBL] [Abstract][Full Text] [Related]
20. [Application of hemopoietic growth factors in therapy].
Stojanović N
Srp Arh Celok Lek; 1995; 123(7-8):208-14. PubMed ID: 17974431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
